Thus, although insulin-stimulated glucose uptake is relatively impaired in the insulin-resistant state, our data suggest that pharmacological hepatic GLUT blockade or targeted hepatic Arg2 activation can drive the therapeutic hepatic glucose response in diet-induced and genetic models of obesity and insulin resistance. This evidence concerns the gene SLC2A1 and obesity disorder.